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ABSTRACT 28 
 29 
Metamizole (MT) is an analgesic and antipyretic drug labelled for use in humans, horses, cattle, 30 
swine and dogs in some countries. MT is rapidly hydrolyzed to the active primary metabolite 4-31 
methyl-amino-antipyrine (MAA). MAA is formed in much larger amounts compared to other minor 32 
metabolites. Among the other secondary metabolites, 4-amino-antipyrine (AA) is also relatively 33 
active. The aim of this research was to evaluate the pharmacokinetic profiles of MAA and AA after 34 
administration of 25 mg/kg MT by intravenous (IV) and intramuscular (IM) routes in healthy 35 
donkeys. Six jennies were randomly allocated to two equally sized treatment groups according to a 36 
2x2 crossover study. Blood was collected at predetermined times within 24 hours and plasma was 37 
analysed by a validated HPLC UV method. Plasma concentrations of MAA after IV and IM 38 
administrations of MT were detectable from 5 minutes to 10 hours in all the donkeys. Plasma 39 
concentrations of AA were detectable from 5 minutes to 8 hours, but in smaller amounts. Cmax (P < 40 
0.01), AUC0-last, AUC0-∞, AUMC0-last and MRT (P < 0.05) were statistically different between the 41 
IV and IM groups. The AUCIM/AUCIV ratio of MAA was 1.37. The AA concentrations were lower 42 
than those found for MAA. The AA plasma vs time curves profiles after the two routes of 43 
administration of MT were variable (within the groups) and different (between the groups). Tmax, λz 44 
and AUC0-last were found to be statistically different between the groups (P < 0.05). The AUCIM 45 
AA/AUCIV AA ratio was 2.26.  46 
 47 
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1. Introduction 50 
 51 
Metamizole (sodium N-[(2,3-dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl)-N-methylamino] 52 
methanesulphonate) (MT), also known as dipyrone, is a pyrazolone derivative [1] introduced to 53 
pharmacotherapy in 1922 in Germany [2]. This is one of the non-opioid analgesic drugs possessing 54 
highest efficacy, used in both human and veterinary medicine for the treatment of pain and fever 55 
[3]. It is a weak COX-1 and COX-2 inhibitor [4] but a strong COX-3 inhibitor [5]. Recently it has 56 
been reported that there is a potential for other likely mechanisms of action because the COX-3 57 
inhibition may not truly explain the pharmacology of this drug [6]. MT is on the human and 58 
veterinary market in several countries (European states, Asia, and South America) but has been 59 
withdrawn in others (Sweden, USA, Japan, UK, Australia, and Iran) because of safety concerns in 60 
humans. Although MT seems to be a relatively safe drug [7,8] compared to other non-opioid 61 
analgesics there is some evidence, which is not unanimously accepted, suggesting that after 62 
prolonged administration MT might damage the haematopoietic system, triggering leukopenia, 63 
agranulocytosis and even aplastic anemia in humans [9,10,11]. However, pharmacovigilance 64 
veterinary data have indicated that the incidence of adverse reactions in the target species is very 65 
low [12]. For veterinary use, MT is administered parentally in the dose range of 20-50 mg/kg body 66 
weight (package leaflet, Biovetalgin, BioWet, Drwalew, Poland).  67 
There is a paucity of data on the pharmacokinetic properties of MT in animals, although the 68 
fate of MT administered to humans has already been described [13]. MT is considered a prodrug 69 
which, in a hydrous environment, undergoes spontaneous breakdown to numerous metabolic 70 
products [13,14]. The parent drug is detectable in serum for just a few minutes after intravenous 71 
administration, but not after oral dosing. It is also not detectable in urine [14]. In humans, MT is 72 
rapidly hydrolyzed to the primary metabolite 4-methyl-amino-antipyrine (MAA). MAA is further 73 
metabolized to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-74 
aminoantipyrine (AA) [13]. AA is acetylated to 4-acetyl-amino-antipyrine (AAA) [13,14,15] (Fig. 75 
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1). MAA and AA are active metabolites [14,16]. The European Medicines Agency (EMA) dossier 76 
reports that in bovine, porcine, and equid species, MAA has been selected as a marker residue for 77 
maximum residue limit (MRL) calculation [12]. 78 
To the best of the authors’ knowledge, only one report is present on the pharmacokinetics of 79 
MAA after MT intravenous administration in horses [17]. As the pharmacokinetics in horses can be 80 
different than in donkeys, the aim of the present study was to evaluate the pharmacokinetic profiles 81 
of MAA and AA after intravenous (IV) and intramuscular (IM) administrations of MT in healthy 82 
donkeys.  83 
 84 
2. Material and Methods 85 
 86 
2.1. Chemicals and Reagents 87 
 88 
Pure MAA and AA analytical standard (> 99.0% purity) were obtained from Toronto 89 
Research Chemicals (Toronto, Canada) and Sigma-Aldrich (St. Louis, MO, USA). The Internal 90 
Standard (IS) metoclopramide powder (> 99.0% purity) was supplied by Sigma-Aldrich (St. Louis, 91 
MO, USA). Donkey control plasma samples were collected in untreated healthy donkeys belonging 92 
to the same herd as the six animals selected for the treatments.  93 
 94 
2.2. Animal Treatment and Sampling 95 
 96 
Six healthy adult Mammoth Jackstock jennies (Equus asinus), aged 7 to 11 years and 97 
weighing 210 to 290 kg were enrolled in the study. The jennies were determined to be clinically 98 
healthy on physical examination, serum chemistry and hematological analyses. Animals were 99 
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evaluated daily (for 1 week) for visible adverse effects by specialized personnel. Animal care and 100 
handling was performed according to the provision of the Directive 2010/63/UE (# 45/2014). 101 
Jennies were acclimatized to the stalls and handlers prior to commencing the study. Animals were 102 
deprived of food for 8 hours prior to the commencement of the experiment while water was 103 
available ad libitum. Hay and water were available ad libitum from 2 hours after treatment 104 
administration. 105 
Animals were randomly allocated to two treatment groups (A=3 and B=3) (six slips of paper 106 
marked with the numbers 1 to 6 in a box) according to an open, single-dose, two-treatment and two-107 
period crossover design experiment. Two jugular venous catheters, one in each side (for MT 108 
administration and for sample collection, respectively), were placed in each animal 1 day prior to 109 
commencement of the study. The group A animals received a single dose of MT (25 mg/kg) by 110 
intravenous injection (IV) (Biovetalgin, injectable solution 500 mg/mL, BioWet, Drwalew, Poland) 111 
while the group B animals received MT at the same dose by intramuscular injection (IM), injected 112 
in the middle quadrant of the neck muscle (Biovetalgin, injectable solution 500 mg/mL, BioWet, 113 
Drwalew, Poland). The dose was selected based on package leaflet recommendations for equid 114 
species. An interval of 1 week (wash-out period) was observed to ensure complete metabolism and 115 
excretion of MAA and AA. After this period, the groups were rotated and the crossover study 116 
completed. By the end of the study, each donkey had received MT by both administration routes. 117 
The blood (3 to 5 mL) was collected via previously inserted catheters at assigned times (0, 15, 30, 118 
45 minutes and 1, 1.5, 2, 4, 6, 8, 10 and 24 hours). The samples were centrifuged at 1,000 x g 119 
within 30 minutes of collection and the harvested plasma was frozen immediately and stored at -20° 120 
C. Samples were analysed within 1 week of collection.  121 
 122 
2.3. HPLC-FL 123 
 124 
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The analytical method was based on a previously described method [18] with slight 125 
modifications [19]. The HPLC system was an LC Jasco (Como, Italy) that consisted of a quaternary 126 
gradient system (PU 2089 PLUS), in line with an ultraviolet detector (Jasco UV-975) set at 254 nm. 127 
The chromatographic separation assay was performed with a Luna C18(2) analytical column (250 128 
mm × 4.6 mm inner diameter, 5 µ particle size [Phenomenex, Bologna, Italy]) preceded by a 129 
security guard column with the same stationary phase (C18(2) [Phenomenex, Bologna, Italy]). The 130 
system was maintained at 25°C. The mobile phase consisted of acetonitrile:amonium acetate (20 131 
mM) solution, pH 5 (20:80, v/v) at a flow rate of 1 mL/min. The elution of the substances was 132 
carried out in isocratic mode. 133 
 134 
2.4. Sample Extraction 135 
 136 
The procedure was performed in a 15 mL polypropylene vial. A 0.5 mL aliquot of plasma 137 
was added to 100 µL of IS (25 µg/mL). After 30 seconds vortexing, 0.1 mL sodium hydroxide (1 138 
N) was added and the sample vortexed again. An aliquot of 4 mL of ethylacetate: methylene 139 
chloride (3:7, v/v) was added, then vortexed (30 seconds), shaken (60 osc/minute, 10 minutes) and 140 
centrifuged at 10,956 x g (rotor radius 5 cm) for 10 minutes at 10°C. Three mL of supernatant was 141 
collected in a new 15 mL screw cap vial. The organic phase was evaporated under a gentle stream 142 
of nitrogen (40°C) and reconstituted with 100 µL of mobile phase. Fifty µL of this solution was 143 
injected onto the HPLC. 144 
 145 
2.5. Pharmacokinetic Analysis and Statistical Analysis 146 
 147 
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The pharmacokinetic calculations were carried out using WinNonlin v 5.3.1 (Pharsight 148 
Corp). The curve fit was performed by a non-compartmental analysis. The pharmacokinetic 149 
parameters are presented as geometric mean and pseudo SD.  150 
In order to make comparisons across treatments, the different parameters were first tested 151 
for normal distribution and variance homogeneity. Data were compared with the paired t-test or the 152 
non-parametric Wilcoxon test, depending on whether the data passed a normality test. In all 153 
experiments, differences were considered significant if P < 0.05. 154 
 155 
3. Results 156 
 157 
The HPLC method was revalidated using control plasma from donkey. Briefly, MAA and AA 158 
were linear in the range of 100–10000 ng/mL. LOD was 30 ng/mL and LOQ was 50 ng/mL, 159 
respectively. When the metabolite concentrations in the samples exceeded the upper limit of the 160 
range, they were re-analysed after appropriate dilution. The intra-day repeatability was lower than 161 
5.2 and 5.9%, whereas accuracy was lower than 4.4 and 5.9% for MAA and AA, respectively. No 162 
behavioural changes or alterations in health parameters were observed in the IV or IM groups of 163 
animals during or after (up to 7 days) the drug administration. 164 
Both the injections (IV and IM) where well tolerated without any discomfort sign, pain or 165 
swelling shown from the animals. Plasma concentrations of MAA after IV administration of MT 166 
were detectable from 5 minutes to 10 hours in all donkeys of both administration groups. The Cmax 167 
of MAA was higher in the IV than in IM group and this concentration was achieved earlier in the 168 
IV group (0.08 vs 0.87 hours). Half an hour after MT injection, the average MAA plasma 169 
concentrations of IV and IM groups became similar. From 1 to 6 hours, MAA plasma 170 
concentrations were higher in the IM than in the IV group (P<0.05). The percent of AUC that was 171 
extrapolated to infinity was always <20% in all the subjects. The average pharmacokinetic curves 172 
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are shown in Fig. 2. The main pharmacokinetic parameters are reported in Table 1. Cmax (P < 0.01), 173 
AUC0-last, AUC0-∞, AUMC0-last and MRT (P < 0.05) were statistically different between the groups. 174 
The mean AUCIM MAA/AUCIV MAA ratio was 1.37.  175 
Plasma concentrations of AA after IV administration of MT were detectable from 5 minutes 176 
to 8 hours in all donkeys of both administration groups. These concentrations were lower than those 177 
found for MAA. The average pharmacokinetic profiles of AA are reported in Fig. 3. The AA 178 
plasma vs time curves profiles after the two routes of administration of MT were variable (within 179 
the groups) and different (between the groups). The AUCIV MAA/AUCIV AA ratio was 23.5 while the 180 
AUCIM MAA/AUCIM AA ratio was 14.2. The main pharmacokinetic parameters are reported in Table 181 
2. Tmax, λz and AUC0-last, were parameters found to be statistically different between the groups (P < 182 
0.05). The AUCIM AA/AUCIV AA ratio was 2.26. 183 
 184 
4. Discussion 185 
 186 
Metamizole, a nonnarcotic analgesic, has been used to treat pain and fever for almost 90 187 
years in some countries, while in others it is completely unknown or forgotten [20]. MT is known to 188 
possess high pain-relieving activity, antipyretic and spasmolytic properties [13] and does not have 189 
the contraindications or limitations usually observed with opioids or NSAIDs [3,21,22,23,24]. MT 190 
has been shown to be a safe and important drug for the management of pain but its use in humans is 191 
still controversial. There is plenty of literature attesting to the analgesic efficacy of MT in human 192 
beings [21,22,23,24,25,26].  193 
In veterinary medicine however, the scenario is totally different since the evidence from 194 
veterinary studies is not as strong as that from the human literature. There are some data available 195 
concerning clinical and side effects of MT in horses [27], rabbits [3], rats [28], and dogs 196 
[8,29,30,31] and some concerning the pharmacokinetic profile of its metabolite MAA in horses 197 
[17,], rats and dogs [32], swine [33] and sheep [19].  198 
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MT is a drug labelled for use in horses, cattle, swine, dogs and cats. In the last few years, 199 
thanks to its attractive pharmacological features, safety profile and low price, there has been a rising 200 
interest in the use of MT in the veterinary field. However, pharmacokinetic-pharmacodynamic data 201 
in donkeys are absent from the literature. A single study [17] reporting the pharmacokinetics of 202 
MAA after a single IV administration of MT in horses is present in the literature. However, the 203 
differences in drug dispositions between horse and donkey are well known and documented in 204 
literature [34,35,36,37,38, 39,40] and the data extrapolations are risky. A species specific study is 205 
needed to evaluate the pharmacokinetics of MT in donkeys. 206 
The overall pharmacokinetic profiles of MAA after IM and IV administrations of MT were 207 
similar. The significant differences found in Cmax values were ascribable to the routes of 208 
administration of MT. The complete/immediate introduction of MT into the vascular compartment 209 
(IV injection) may have generated, in the initial minutes, a more rapid metabolic conversion 210 
(increasing the Cmax of MAA) compared to the IM injection where an absorption phase is expected. 211 
The absorption phase may also be responsible for the difference in Tmax. The larger AUCs, t1/2 λz 212 
and MRT values found in the IM group are likely due to the gradual release of drug from the 213 
injection site to the vascular system. Despite the abrupt peak of MAA concentration following IV 214 
administration, no adverse effects were shown in the animals.  215 
The plasma concentrations of MAA detected in the present study were higher than those 216 
previously observed in horses [17], administered with the same dose of MT. However, the drug 217 
administered in the horse study [17] was a combination product labelled for humans which also 218 
contained hyoscine butylbromide (Buscopan compositum, Boehringer-Ingelheim, Ingelheim, 219 
Germany). Pharmacokinetic interactions between the two active compounds might have affected the 220 
MT metabolism or the MAA kinetics. However, the AUC0-∞ values of MAA are comparable 221 
between the studies. 222 
The half-life reported in the present study was shorter than those previously reported in dogs 223 
(4-5 hours; [41]) and horses (4.85 hours; [17]) but similar to that reported in sheep (1.45-3 hours; 224 
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[19]). The reason for this difference might be due to a number of factors such as: differences in 225 
animal species, route of administration, presence of pathophysiological conditions, age of the 226 
animals, and sensitivity of the analytical method. Volume of distribution (assuming that all MT is 227 
transformed into MAA) is large, a finding in line with the chemical/physical features of MAA, for 228 
example it is detected in cerebrospinal fluid [42]. 229 
Diverse pharmacokinetic trends have been found for the AA metabolite after IM and IV 230 
administrations of MT. As a result, the AUC0-last value of the IV group was half that found in the IM 231 
group. The abrupt peak of MAA concentration following IV administration might have saturated 232 
the metabolic pathway MAA to AA, metabolizing (oxidizing) a proportion of MAA to FAA 233 
(inactive metabolite). This might explain why the Cmax values of AA between the groups are not 234 
statistically different. Further studies evaluating all the metabolites formed in the donkey are 235 
necessary to clarify this issue.  236 
In humans the analgesic effect of MT correlates with the concentration of MAA and AA, 237 
which differ with regard to their time of onset (MAA > AA) and terminal half-life (MAA: 4-5 238 
hours, AA: 5–8 hours) [20]. MAA is around 50 times more active than MT as an inhibitor of COX, 239 
while AA is less active than MT. Therefore both metabolites can contribute to the clinically relevant 240 
features of rapid onset and long duration of the effect, permitting 8–10 hourly dosing intervals. The 241 
other 2 metabolites, FAA and AAA, are inactive. The metabolites which generate the analgesic 242 
action, are still unknown in the donkey. According to the drug producer, a 25 mg/kg injection of 243 
MT is an effective dose to relieve pain in equid species for 10 hours. If we assume that analgesic 244 
activity in the donkey is only attributable to MAA and AA metabolites as in humans, the 245 
contribution of AA to the overall therapeutic activity might be negligible due to its negligible 246 
plasma concentrations and activity. Hence, it might be presumed that MAA is the main metabolite 247 
responsible for the effect. A gross calculation of the average plasma concentration of this metabolite 248 
(which is likely to produce pain relief in the donkey), in other words its minimal effective 249 
concentration, might theoretically be calculated as AUC0-last/10 hours and approximated to be above 250 
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8 µg/mL. Further studies are necessary to confirm this theoretical data and to establish if the 251 
metabolic pattern reported in humans matches that in donkeys, as well as pharmacodynamic studies 252 
to determine its efficacy in different types of pain. 253 
 254 
5. Conclusions 255 
 256 
This is the first study reporting the pharmacokinetics of MAA and AA after IV and IM 257 
administration of MT in donkeys. The IV administration of MT elicits MAA plasma concentration 258 
lower than that after IM administration, while twice the amount of AA is formed after IM 259 
administration of MT. Although further studies are needed to understand the metabolic pathway of 260 
MT as well as its safety profile, the difference reported in AA concentrations might be clinically 261 
negligible in donkeys. 262 
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Figures’ captions 393 
Fig. 1. Metabolic pathway of metamizole (MT) reported in humans [41]. 394 
 395 
Fig. 2. Mean plasma concentrations of 4-methyl-amino-antipyrine (MAA) vs. time curves following 396 
intravenous (─●─) and intramuscular (--○--) administrations of 25 mg⁄kg metamizole (MT) in 397 
healthy jennies (n = 6). Bars represent the standard deviations. * Statistically different between the 398 
groups. 399 
 400 
Fig. 3. Mean plasma concentrations of 4-aminoantypyrine (AA) vs. time curves following 401 
intravenous (─●─) and intramuscular (--○--) administrations of 25 mg⁄kg metamizole (MT) in 402 
healthy jennies (n = 6). Bars represent the standard deviations. * Statistically different between the 403 
groups. 404 
 405 
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Table 1 
  
 
                    
  
  
                  
                      
                      
                      
        IV       IM     
  Parameter   Mean   SD   Mean   SD   
  R2   0.98 ± 0.01   0.94 ± 0.04   
  λz (1/h)   0.40 ± 0.10   0.35 ± 0.10   
  t1/2 λz (h)   1.81 ± 0.49   1.94 ± 0.79   
  Tmax (h)   0.08 ± 0.00   0.87 ± 0.12   
  Cmax (µg/mL)*   211.72 ± 21.58   46.33 ± 13.23   
  AUC0-last (h µg/mL) * 82.92 ± 5.46   113.44 ± 45.02   
  AUC0-∞ (h µg/mL) * 83.01 ± 5.46   120.33 ± 55.12   
  Vz/F (mL/kg)   786.23 ± 221.33   503.01 ± 389.67   
  Cl/F (mL/h/kg)   301.42 ± 20.01   161.58 ± 195.42   
  AUMC0-∞ (h2 µg/mL)* 92.23 ± 14.67   273.98 ± 112.41   
  MRT (h) *   1.04 ± 0.13   2.99 ± 1.04   
 
  
 
                    
                      
                      
                      
                      
                      
                      
 
Table 1  
Main pharmacokinetic parameters of 4-methyl-amino-antipyrine (MAA) following single intravenous (IV) and 
intramuscular (IM) administrations of metamizole (MT) (25 mg/kg) in healthy jennies (n=6). 
R
2 
= correlation coefficient; λz = terminal phase rate constant; t1/2λz = terminal half-life; Tmax = time of peak; Cmax 
= peak plasma concentration; AUC0−last= area under the plasma concentration-time curve; AUC0-∞= area under the 
plasma concentration-time curve extrapolated to infinity; Vz/F = apparent volume of distribution; Cl/F = apparent 
clearance; AUMC0-∞= area under the first moment curve from zero to infinity; MRT = mean resident time. 
Parameters values are expressed as geometric mean, while t1/2 λz as harmonic mean. PSD = pseudo standard 
deviation. * Statistically different value between the treatment groups. 
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Table 2 407 
 408 
 
  
 
                    
                      
                      
                      
        IV       IM     
  Parameter   Mean   PSD   Mean   PSD   
  R2   0.90 ± 0.15   0.97 ± 0.01   
  λz (1/h)*   0.17 ± 0.02   0.26 ± 0.06   
  t1/2 λz (h)   3.87 ± 0.56   2.68 ± 0.94   
  Tmax (h)*   0.16 ± 0.09   0.94 ± 0.23   
  Cmax (µg/mL)   2.82 ± 2.13   2.36 ± 0.85   
  AUC 0-last (h µg/mL)* 3.52 ± 0.81   7.98 ± 2.13   
  MRT (h)   4.58 ± 0.81   4.56 ± 1.06   
 
  
 
                
  
  
                      
                      
    
                      
 409 
R
2 
= correlation coefficient; λz = terminal phase rate constant; t1/2λz = terminal half-life; Tmax = 
time of peak; C
max
 = peak plasma concentration; AUC0−last= area under the plasma 
concentration-time curve; MRT = mean resident time. 
Parameters values are expressed as geometric mean, while t1/2 λz as harmonic mean. PSD = 
pseudo standard deviation. * Statistically different value between the treatment groups. 
Table 2  
Main pharmacokinetic parameters of 4-amino-antipyrine (AA) following single intravenous 
(IV) and intramuscular (IM) administrations of metamizole (MT) (25 mg/kg) in healthy 
jennies (n=6). 
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Fig. 2.  414 
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Fig. 3.  417 
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Highlights 
Metamizole is metabolized in vivo in donkeys 
4-methylamino-antipyrine is produced in larger amounts than 4-acetylamino-antipyrine  
After IM and IV administration of metamizole, the plasma profiles of the metabolites are different 
